what's happening with semaglutide FDA Warns on Certain Forms of Compounded Semaglutide for Weight Loss: How

Obesity or Overweight : GLP-1 medications are prescribed to individuals who are overweight (BMI of 27 or higher) or obese (BMI of 30 or higher) and may have obesity-related health conditions (e.g., type 2 diabetes, hypertension)

Clinical data shows approximately 5070% of weight lost returns within 12 months of stopping treatment, though the timeline and amount vary significantly between individuals

Symptoms can be episodic occurring in distinct flares separated by relatively asymptomatic periods or chronic and persistent, varying in severity from mildly disruptive to profoundly debilitating

Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis

Diabetes Care 37:e76-77 Goldstone AP, Holland AJ, Butler JV, Whittington JE (2012) Appetite hormones and the transition to hyperphagia in children with PraderWilli syndrome

Gross, L.M